FDA Allows Broader Indications For Oncology Companion Dx’s
New guidance from the US agency discusses how manufacturers can pursue broader indications for oncology companion diagnostics. The move could make it easier for clinicians to find the best treatment for each patient.
You may also be interested in...
US FDA is proposing to allow cancer IVD-makers to label their tests for certain types of cancers and their therapies instead of limiting them to specific drugs and biologics. The agency says the expanded labeling is crucial to giving patients more options and help target treatments.
The agency allows IVD developers to use assays with different instrument systems without submitting a new 510(k), as long as they meet certain safety and efficacy criteria.
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.